Norges Bank’s KalVista Pharmaceuticals KALV Stock Holding History

Norges Bank’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-131,300	Closed	-$1.55M	–	1903
2024 Q2	$1.55M	Buy	+131,300	New	+$1.53M	﹤0.01%	1765
2023 Q1	–	Sell	-218,900	Closed	-$1.48M	–	2128
2022 Q4	$1.48M	Buy	218,900 +204,000	+1,369%	+$1.09M	﹤0.01%	2009
2022 Q3	$216K	Hold	14,900	–	–	﹤0.01%	2075
2022 Q2	$147K	Buy	+14,900	New	+$164K	﹤0.01%	2044
2020 Q4	–	Sell	-21,400	Closed	-$269K	–	2138
2020 Q3	$269K	Sell	21,400 -72,000	-77%	-$900K	﹤0.01%	2109
2020 Q2	$1.13M	Buy	+93,400	New	+$993K	﹤0.01%	2003

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Norges Bank's KALV Position: Q3 2024 in Review

Norges Bank sold out of KalVista Pharmaceuticals (KALV) in Q3 2024, closing a stake of 131,300 shares — an estimated $1.55M sold.

Norges Bank first reported a position in KALV in Q2 2020 and held it in 6 quarters. The position peaked at $1.55M in Q2 2024. 122 funds tracked by Wall St. Rank hold KALV as of Q3 2024.

Norges Bank reported no remaining KalVista Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Norges Bank sold 131,300 KalVista Pharmaceuticals shares in Q3 2024, an estimated $1.55M.
Norges Bank first reported a position in KalVista Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Norges Bank's KalVista Pharmaceuticals position peaked at $1.55M in Q2 2024.
122 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2024.

Based on Norges Bank's 13F filing for Q3 2024, filed 13 Nov 2024.